Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Eye, Ear & Vision

Therapeutic Outcomes of Combined Eyelid Hygiene, Intense Pulsed Light, and Meibomian Gland Expression in Meibomian Gland Dysfunction

The standard combination therapy resulted in significant and durable improvements in approximately 70% of MGD patients, with effects persisting for at least 3 months post-treatment.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

This retrospective study of 107 patients with meibomian gland dysfunction examined a combined therapy of eyelid hygiene, intense pulsed light and gland expression over at least six months. The authors report that the standard three-session course was associated with significant improvements in several ocular surface measures in about 70% of patients, with effects lasting at least three months. The study's retrospective design limits causal conclusions.

Participants
107
Who or what was studied
Patients with meibomian gland dysfunction who completed at least three combination therapy sessions, with a minimum six-month follow-up; 77 females and 30 males were enrolled, 74 in the standard group and 33 in the extended group.
Limits stated in the abstract
The study is retrospective, so the findings are associational and no causal effect of the therapy can be concluded from the abstract.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background/Objectives

This study aimed to assess the effectiveness of a combination therapy comprising eyelid hygiene, intense pulsed light (IPL), and meibomian gland expression in patients with meibomian gland dysfunction (MGD).

Methods

This retrospective study included MGD patients who completed at least three sessions of combination therapy administered at 4-week intervals, with a minimum follow-up period of 6 months. Ocular surface parameters were evaluated at baseline and at 1, 3, and 6 months after treatment initiation. Based on the clinical response following the initial three sessions, patients were categorized into either the standard treatment group (3 sessions) or the extended treatment group, who received three additional sessions of the same combination therapy.

Results

A total of 107 patients (77 females; 30 males) were enrolled. 74 patients received standard treatment, and 33 received extended treatment. In the standard group, significant improvements compared with baseline were observed in the Ocular Surface Disease Index score, non-invasive tear break-up time, corneal staining, lid margin plugging, telangiectasia, and the meibomian gland expressibility score. Conversely, in the extended group, only the meibomian gland expressibility score showed significant improvements at the 3-month follow-up.

Conclusions

The standard combination therapy resulted in significant and durable improvements in approximately 70% of MGD patients, with effects persisting for at least 3 months post-treatment. These findings support the clinical utility of this multimodal approach and highlight the need for biomarkers to predict treatment response.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a single study: what to check before relying on this kind of research.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies